Stock Analysis

Undiscovered Gems with Strong Potential for August 2024

KASE:MARI
Source: Shutterstock

As global markets experience heightened volatility and economic indicators show mixed signals, the focus has shifted towards identifying resilient opportunities within the small-cap sector. In this environment, finding stocks with strong fundamentals and growth potential can be particularly rewarding.

Top 10 Undiscovered Gems With Strong Fundamentals

NameDebt To EquityRevenue GrowthEarnings GrowthHealth Rating
Impellam Group31.12%-5.43%-6.86%★★★★★★
Ovostar Union0.01%10.19%49.85%★★★★★★
Etihad Atheeb TelecommunicationNA26.82%62.18%★★★★★★
Tianyun International Holdings10.09%-5.59%-9.92%★★★★★★
Britam Holdings10.05%3.47%16.62%★★★★★☆
Societe de Limonaderies et de Boissons Rafraichissantes d'Afrique39.37%8.04%-3.72%★★★★★☆
Standard Chartered Bank Kenya6.93%8.35%16.18%★★★★☆☆
Central Cooperative Bank AD4.88%4.12%8.95%★★★★☆☆
Wilson64.79%30.09%68.29%★★★★☆☆
A2B Australia15.83%-7.78%25.44%★★★★☆☆

Click here to see the full list of 4779 stocks from our Undiscovered Gems With Strong Fundamentals screener.

Let's review some notable picks from our screened stocks.

Dutch-Bangla Bank (DSE:DUTCHBANGL)

Simply Wall St Value Rating: ★★★★☆☆

Overview: Dutch-Bangla Bank PLC offers a range of commercial banking products and services to corporate, retail, and institutional customers in Bangladesh, with a market cap of BDT50.09 billion.

Operations: Dutch-Bangla Bank PLC generates revenue primarily from interest income and fees related to its commercial banking services. The bank's net profit margin is 15.45%.

Dutch-Bangla Bank, with total assets of BDT631.1B and equity of BDT48.8B, boasts a price-to-earnings ratio of 6.5x, significantly lower than the BD market average of 22.1x. The bank’s earnings grew by 30.4% over the past year, outpacing the industry growth rate of 27.4%. It has high bad loans at 5.7%, but maintains low-risk funding with customer deposits making up 86% of liabilities and an allowance for bad loans at 63%.

DSE:DUTCHBANGL Earnings and Revenue Growth as at Aug 2024
DSE:DUTCHBANGL Earnings and Revenue Growth as at Aug 2024

Square Pharmaceuticals (DSE:SQURPHARMA)

Simply Wall St Value Rating: ★★★★★☆

Overview: Square Pharmaceuticals PLC. and its subsidiaries develop, manufacture, and market drugs for healthcare for various live species in Bangladesh, with a market cap of BDT209.56 billion.

Operations: Square Pharmaceuticals PLC generates revenue primarily from its pharmaceuticals segment, which amounted to BDT68.81 billion. The company's market cap stands at BDT209.56 billion.

Square Pharmaceuticals, trading at a P/E ratio of 10.4x versus the BD market's 22.1x, offers an attractive valuation. With earnings growth of 7.3% over the past year, it outperformed the broader pharmaceuticals industry which saw a -2.8% decline. The company has more cash than total debt and boasts high-quality earnings, ensuring financial stability and interest coverage is not an issue. Future projections indicate annual earnings growth of 12.18%.

DSE:SQURPHARMA Earnings and Revenue Growth as at Aug 2024
DSE:SQURPHARMA Earnings and Revenue Growth as at Aug 2024

Mari Petroleum (KASE:MARI)

Simply Wall St Value Rating: ★★★★★☆

Overview: Mari Petroleum Company Limited explores for, produces, and sells hydrocarbons in Pakistan with a market cap of PKR381.37 billion.

Operations: Mari Petroleum generates revenue primarily from its Oil & Gas - Exploration & Production segment, amounting to PKR166.18 billion.

With a price-to-earnings ratio of 5.7x, Mari Petroleum offers better value compared to the PK market's 6.5x. Over the past year, earnings surged by 47%, outpacing the Oil and Gas industry’s -12.7%. The company has more cash than its total debt, indicating strong financial health. Additionally, Mari's debt-to-equity ratio rose from 0.2% to 0.4% over five years while maintaining high-quality earnings and positive free cash flow throughout this period.

KASE:MARI Debt to Equity as at Aug 2024
KASE:MARI Debt to Equity as at Aug 2024

Turning Ideas Into Actions

Contemplating Other Strategies?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com